Key Details
Price
$62.10Annual ROE
-6.60%Beta
0.43Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Citi Global Healthcare Conference, Miami Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET Evercore HealthCONx Conference, Miami Fireside chat on Wednesday, December 4, 2024 at 7:30 a.m. ET The webcasts can be accessed in the.
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. “Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes fo.
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase.
Exact Sciences presents new positive evidence backing the development of an MCED test.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening m.
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
FAQ
- What is the primary business of Exact Sciences?
- What is the ticker symbol for Exact Sciences?
- Does Exact Sciences pay dividends?
- What sector is Exact Sciences in?
- What industry is Exact Sciences in?
- What country is Exact Sciences based in?
- When did Exact Sciences go public?
- Is Exact Sciences in the S&P 500?
- Is Exact Sciences in the NASDAQ 100?
- Is Exact Sciences in the Dow Jones?
- When was Exact Sciences's last earnings report?
- When does Exact Sciences report earnings?
- Should I buy Exact Sciences stock now?